Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2026-01-01 @ 5:02 PM
Study NCT ID:
NCT05431504
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-06-24
First Post:
2022-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-19
First Submit QC Date:
None
Study First Post Date:
2022-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-19
Last Update Post Date:
2022-06-24
Last Update Post Date Type:
ACTUAL